CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute)

N/A

Report date: 2024/05/27 20:00:49

Base Information

Drug NameCAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionG-protein coupled receptor family C group 5member D modulatorsB-cell maturation protein modulators
TargetsG-protein coupled receptor family C group 5member DB-cell maturation protein
Therapy Area/IndicationsPlasmacytomaMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian FederationMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Geno-Immune Medical InstituteThe No.2 Clinical Hospital of the Ministry of Health
China Registration ClassN/A

Develop Information

Active CompaniesThe No.2 Clinical Hospital of the Ministry of HealthShenzhen Geno-Immune Medical Institute
Inactive CompaniesN/A
Active IndicationsPlasmacytomaMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A